medroxyprogesterone acetate

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

medroxyprogesterone acetate

Apo-Medroxy (CA), Climanor (UK), Depo-Provera, Depo-SUBQ-Provera 104, Dom-Medroxyprogesterone (CA), Gen-Medroxy (CA), Novo-Medrone (CA), PMS-Medroxyprogesterone (CA), Provera, Ratio-MPA

Pharmacologic class: Hormone

Therapeutic class: Progestin

Pregnancy risk category X

FDA Box Warning

• Injection form may cause significant bone density loss. Loss increases with duration of use and may not be completely reversible. It is unknown if use during adolescence or early adulthood reduces peak bone mass and increases risk for osteoporotic fracture later in life.

• Injection form should be used as long-term contraceptive (more than 2 years) only if other contraceptive methods are inadequate.


Inhibits pituitary gonadotropin secretion, preventing follicular maturation, ovulation, and pregnancy


Suspension for depot injection: 150 mg/ml, 400 mg/ml

Suspension for depot subcutaneous injection: 104 mg/0.65 ml in prefilled single-use syringes

Tablets: 2.5 mg, 5 mg, 10 mg

Indications and dosages

Secondary amenorrhea

Adults: 5 to 10 mg/day P.O. for 5 to 10 days, starting at any time during menstrual cycle

Dysfunctional uterine bleeding; menses induction

Adults: 5 to 10 mg/day P.O. for 5 to 10 days, starting on day 16 or 21 of menstrual cycle

To prevent estrogen-related endometrial changes in postmenopausal women

Adults: 2.5 to 5 mg/day P.O. given with 0.625 mg conjugated estrogens P.O. (monophasic regimen); or 5 mg/day P.O. on days 15 to 28 of cycle, given with 0.625 mg conjugated estrogens P.O. daily throughout cycle (biphasic regimen)

Management of endometriosis-associated pain

Adults: 104 mg (Depot-subcutaneous-Provera) in anterior thigh or abdomen q 12 to 14 weeks

To prevent pregnancy

Adults: 150 mg (Depo-Provera) deep I.M. injection q 13 weeks or 104 mg (Depot-subcutaneous-Provera) in anterior thigh or abdomen q 12 to 14 weeks. Give first injection during first 5 days of normal menstrual period or first 5 postpartal days if patient isn't breastfeeding, or during sixth postpartal week if patient is breastfeeding exclusively.

Renal or endometrial cancer

Adults: 400 to 1,000 mg I.M.; may repeat weekly. If improvement occurs, decrease to 400 mg q month.

Off-label uses

• Advanced breast cancer


• Hypersensitivity to drug or its components

• Cerebrovascular or thromboembolic disease

• Hepatic dysfunction or disease

• Breast or genital cancer

• Undiagnosed vaginal bleeding

• Known or suspected pregnancy


Use cautiously in:

• seizure disorder, renal or cardiovascular disease, asthma, diabetes mellitus, depression, migraine

• history of hepatic disease.


• Before starting therapy, obtain thorough history and physical examination, with emphasis on breast and pelvic organs. Also obtain Pap smear, and repeat annually during therapy.

• With contraceptive use, rule out pregnancy before first dose and when more than 14 weeks have passed since previous dose.

• For I.M. injection, inject deep into gluteal, deltoid, or anterior thigh muscle. Rotate injection sites.

• Be aware that when drug is used to prevent estrogen-related endometrial changes in postmenopausal women, lowest dosage should be used for shortest time, because treatment exceeding 1 year correlates with cancer. (Some combination products have 0.3 mg estrogen/1.5 mg progesterone or 0.45 mg estrogen/1.5 mg progesterone.)

Adverse reactions

CNS: insomnia, migraine, nervousness, drowsiness, dizziness, fatigue, depression, mood changes

CV: thrombophlebitis, thromboembolism

EENT: diplopia, proptosis, retinal vascular lesions, papilledema

GI: abdominal pain, bloating

GU: amenorrhea, leukorrhea, spotting, cervical secretions, galactorrhea, breast tenderness and secretion, cervical erosions, pelvic pain, infertility

Hepatic: jaundice

Metabolic: fluid retention, hyperglycemia

Musculoskeletal: leg cramps, back pain

Respiratory: pulmonary embolism

Skin: pruritus, urticaria, rash, acne, alopecia, hirsutism, chloasma, melasma, sterile abscesses, induration at I.M. site

Other: weight and appetite changes, edema, angioedema, allergic reactions including anaphylaxis


Drug-drug. Bromocriptine: decreased bromocriptine efficacy

Carbamazepine, phenobarbital, phenytoin, rifampin: decreased contraceptive efficacy

Drug-diagnostic tests. Alkaline phosphatase, low-density lipoproteins: increased levels

High-density lipoproteins, pregnanediol excretion: decreased levels

Thyroid hormone assays: altered results

Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring

• Monitor patient for fluid retention and for signs and symptoms of thrombophlebitis, including pain, swelling, and redness of lower legs.

Assess for visual disturbances and headache. If ocular exam shows papilledema or retinal vascular lesions, drug should be discontinued.

• Evaluate liver function tests.

Watch for abdominal pain, fever, malaise, jaundice, darkened urine, and clay-colored stools.

Patient teaching

• Advise patient that drug may cause nausea, vomiting, headache, abdominal pain, painful breast swelling, and abnormal bleeding pattern. Instruct her to report these effects if pronounced.

Tell patient to promptly report bloating, swelling, appetite loss, rash, yellowed skin, mood changes or depression, nervousness, dizziness, chest pain, shortness of breath, visual disturbances, or severe headache.

• Teach patient how to perform breast self-exams.

• Tell patient she must undergo yearly physical examinations with Pap smear.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

medroxyprogesterone acetate

A progestin, C24H34O4, used as an injectable contraceptive, in the treatment of amenorrhea and uterine bleeding, and, in combination with estrogen, in hormone replacement therapy.

medroxyPROGESTERone acetate

a progestin.
indications It is prescribed in endometrial and renal carcinomas and in the treatment of menstrual disorders caused by hormone imbalance. It is given as a depot injection for contraception (Depo-Provera).
contraindications Known or suspected pregnancy, thrombophlebitis, embolism, stroke, liver dysfunction, cancer of the breast or genitals, abnormal vaginal bleeding, missed abortion, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse effects are thrombophlebitis, pulmonary embolism, stroke, hepatitis, and cerebral thrombosis.

medroxyprogesterone acetate

A synthetic progestin, which is chemically similar to androgen. Medroxyprogesterone acetate is used primarily as a contraceptive; it is injected every three months, inhibiting gonadotropin secretion which, in turn, prevents follicular maturation and ovulation, and causes endometrial thinning.

Contraceptive, hormone replacement therapy, treatment of endometriosis, anti-androgenic for male sex offenders (causing chemical castration).
Adverse effects
Acne, dysmenorrhoea, birth defects if taken during pregnancy, headache, breast tenderness, increased facial hair, decreased scalp hair, insomnia, abdominal pain/discomfort, dizziness, asthenia (weakness or fatigue), and weight changes. It also carries an increased risk of coronary heart disease, breast cancer, stroke and pulmonary embolism.

medroxyprogesterone acetate

Provera® Gynecology A contraceptive injected every 3 months, whichs inhibits gonadotropin secretion which, in turn, prevents follicular maturation and ovulation, and causes endometrial thinning Adverse effects Menstrual irregularities, weight changes, headache, nervousness, abdominal pain/discomfort, dizziness, asthenia–
weakness or fatigue. See Contraceptive.

medroxyprogesterone acetate

a synthetic progestogen used for estrus control and the treatment of behavioral problems in dogs and cats; abbreviated MPA.
References in periodicals archive ?
Suppressive action of norethisterone enanthate and depo medroxyprogesterone acetate on gonadotropin levels.
Additional studies would require a comparison group of young women on depot medroxyprogesterone acetate who did not experience declines in BMD.
Depo subQ provera 104 is a new formulation of medroxyprogesterone acetate, which is the active ingredient in Depo-Provera Contraceptive Injection (medroxyprogesterone acetate injectable suspension), but with 30% less hormone.
Participants were randomly assigned to usual care (control group), estrogen therapy with micronized 17 B-estradiol alone (estrogen group), or 17 B-estradiol plus sequentially administered medroxyprogesterone acetate (estrogen-progestin group).
brand and authorized generic sales of Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg/mL, 1mL vials, and 1mL prefilled syringes were approximately $316 million for the 12 months ended September 30, 2017.
Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Harel said the results were worrisome enough for him to recommend measuring total 25(OH)D in adolescent girls using depot medroxyprogesterone acetate.
While depot medroxyprogesterone acetate (DMPA) is a highly effective contraceptive used by millions of women, its use is associated with bone mineral density loss, raising concerns about long-term risk of osteoporosis and/or fractures.
5 mg of medroxyprogesterone acetate daily) for menopausal symptoms also had higher risks of cardiovascular disease, coronary heart disease, stroke, and venous thromboembolism, along with lower risks of fracture and of colorectal cancer, compared with those not on HT.
The antiovulatory concentrations of medroxyprogesterone acetate achieved within 24 hours of injection provide almost immediate protection against pregnancy and likely contribute to the high contraceptive efficacy seen with DMPA-IM.
Each of the recruits had failed to improve while taking medroxyprogesterone acetate, a first-line hormonal treatment, and was willing to have a hysterectomy, says study coauthor Miriam Kuppermann, an epidemiologist at the University of California, San Francisco (UCSF).